Literature DB >> 2462299

Surgical management of benign prostatic obstruction.

W K Mebust1.   

Abstract

The incidence of transurethral resection of the prostate (TURP) and indications for prostatectomy are compared among earlier studies with the preliminary results of a recent national cooperative study of 3,885 patients undergoing transurethral prostatectomies at thirteen health centers in the United States. Clinical evidence indicates that TURP continues to be a successful procedure, with 97 percent of patients doing well in the first four months postoperatively in the most recent study. Although the incidence of TURP-related morbidity has been relatively consistent among three large-scale studies conducted during the past three decades, mortality has steadily declined from 2.5 percent to 0.2 percent.

Entities:  

Mesh:

Year:  1988        PMID: 2462299

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Is there a difference in early perioperative morbidity in transurethral resection of prostate (TURP) versus TURP with cystolitholapaxy and TURP with inguinal herniorrhaphy?

Authors:  M Hammad Ather; Nuzhat Faruqui; Fuad Abid; M Nasir Sulaiman
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 2.  Interventional radiology of the lower urinary tract and its relationship to surgical treatment.

Authors:  F Castañeda; J M Hernández-Graulau; W R Castañeda-Zúñiga
Journal:  Cardiovasc Intervent Radiol       Date:  1991 Jul-Aug       Impact factor: 2.740

3.  Bladder-outlet obstruction--assessment of symptoms.

Authors:  J M Reynard; P Abrams
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

Review 4.  Benign prostatic hyperplasia.

Authors:  R J Simpson
Journal:  Br J Gen Pract       Date:  1997-04       Impact factor: 5.386

5.  Transurethral thermotherapy in the management of benign prostatic hyperplasia.

Authors:  F Sofras; G Sakkas; D Kontothanassis; F Lyssiotis; N Tamvakis
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.